Phenazid® (Fenazid® )

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceIsonicotinoylhydrazine iron sulfateIsonicotinoylhydrazine iron sulfate
Similar drugsTo uncover
  • Phenazid®
    pills inwards 
       
    • Dosage form: & nbsppills
    Composition:
    one tablet contains:
    Active substance:
    Isonicotinoylhydrazine iron sulfate dihydrate (phenazid®) 250 mg
    Excipients: potato starch - 57 mg, calcium stearate monohydrate - 3 mg

    Description:Tablets of flat-cylindrical form with a facet and duckweed of yellowish-brown color with impregnations
    Pharmacotherapeutic group:anti-tuberculosis drug
    ATX: & nbsp

    J.04.A.K   Other antituberculous drugs

    Pharmacodynamics:
    Fenazid® is an antituberculous drug. Is active against mycobacteria tuberculosis. The pharmacological action of phenazide ® is based on the modification of the isoniazid molecule by complexation with iron. This provides chemotherapy for tuberculosis, since the iron-blocked chelate of the isonicotinic acid hydrazide molecule (GINC) loses its ability to interact with the active centers of the metal-containing enzymes, and the inclusion of the primary amino group of hydrazine in the complex chelate cycle interferes with the interaction with the N-acetyltransferase.
    In this regard, phenazide is a low-toxic drug, the use of which does not require the correction of single and course doses of the drug in | depending on the rate of its acetylation.

    Pharmacokinetics:Fenazid® is slowly absorbed, the time to reach the maximum concentrations of the drug in the blood is 5-6 hours, the half-life is 7.2 hours.
    Indications:
    Fenazid® is indicated for the complex therapy of tuberculosis patients with different localization, including concomitant diseases of the central nervous system, liver and poor tolerance of isonicotinic acid hydrazide preparations (GINC).

    Contraindications:Hypersensitivity, pulmonary heart failure, ischemic heart disease (IHD), impaired blood clotting, thyroid dysfunction, pregnancy, breast-feeding, children's age.
    Pregnancy and lactation:Contraindicated
    Dosing and Administration:Inside, after 30-40 minutes. after meal. On the first day, take 250 mg (1 table) in the morning (to clarify individual tolerability), then, in the absence of adverse reactions, 250 mg in the morning and in the evening, for 6 months.
    Side effects:
    Possible cardiotoxic effect, acceleration of troop formation, myocarditis, headache, dyspeptic disorders, hypothyroidism of the thyroid gland, hemosiderosis of the parenchymal organs.

    Overdose:
    Symptoms: increased severity of adverse reactions.
    Treatment: withdrawal of the drug, gastric lavage, symptomatic therapy. Specific antidote is not installed.

    Interaction:Since phenazid® is a derivative of the GINK (chelate complex of isoniazid and ferrous iron), the combined use of phenazide® and isoniazid is contraindicated.
    Special instructions:During the treatment with phenazide ®, a systematic (at least once a month) monitoring of the electrocardiogram and coagulogram is necessary.
    Form release / dosage:
    Tablets 250 mg.
    Packaging:For 50 pieces in a polymer jar or 10 tablets in a contour squad package. Each jar or 5 contour mesh packages together with the instruction for use is placed in a pack of cardboard.
    Storage conditions:In dry, dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:3 years. Do not use after the time specified on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:P N001200 / 02
    Date of registration:16.01.2008
    Manufacturer: & nbsp
    Information update date: & nbsp11.09.2012
    Illustrated instructions
      Instructions
      Up